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Abstract
Background: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize 
treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare 
the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year 
follow-up.
Method: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two 
first-episode, drug-naïve patients were randomly assigned to aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) 
and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an 
analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy.
Results: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among 
treatment groups (aripiprazole = 73.08%, ziprasidone = 79.03%, and quetiapine = 95.16%) (χ2 = 11.680; P = .001). Statistically 
significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along 
the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank = 32.260; P = .001). 
Significant differences between treatments were found in the categories of sleepiness/sedation (χ2 = 9.617; P = .008) and 
increased sleep duration (χ2 = 6.192; P = .004). No significant differences were found in the profile of extrapyramidal symptoms. 
Patients on aripiprazole were more likely to be prescribed benzodiazepines.
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Conclusions: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. 
Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.
Keywords: antipsychotic agents, schizophrenia, first-episode psychosis, effectiveness
Introduction
The early stages after the onset of a first episode of psych-
osis (FEP) are crucial for the long-term outcome of the disease 
(Robinson et al., 2005). The course and outcome of schizophre-
nia are characterized by mainly unexplained heterogeneity (van 
Os and Kapur, 2009), showing good outcome in <50% of patients 
(Menezes et al., 2006; Lally et al., 2017). Additionally, three-quar-
ters of all patients who experience a remission from an FEP will 
have a recurrence of psychotic symptoms within a year of treat-
ment discontinuation, and 95% to 100% of these may experience 
clinical deterioration (Zipursky et al., 2014). In this sense, pre-
vention of recurrent episodes is likely to be critical to prevent 
disease progression (Lieberman et al., 2008; Emsley et al., 2013a), 
and nonadherence to medication seems to represent the high-
est risk factor (a 4-fold risk) for relapse after an FEP (Alvarez-
Jimenez et  al., 2012; Caseiro et  al., 2012; Emsley et  al., 2013b; 
García et al., 2016). Given that currently it is not possible to dis-
cern clearly those individuals that will stay in a benign course 
from those with a more severe outcome (Leucht et  al., 2012), 
maintenance treatment should be the preferred option even 
in stable patients after an FEP to remain in recovery (Buchanan 
et al., 2010; Gaebel et al., 2011). In recent years, this recommen-
dation has been challenged by concerns about the potential 
antipsychotics long-term adverse outcomes (Wunderink et al., 
2013; Gotzsche et  al., 2015; Moncrieff, 2015) such as antipsy-
chotic-induced dopamine D2 receptor sensitization, brain vol-
ume loss, metabolic syndrome, and other negative effects on 
physical health (Murray et al., 2016; Goff et al., 2017). These con-
cerns have been minimized by the results of large cohort studies 
published in recent years indicating that the use of antipsychot-
ics is associated with a lower risk of death or severe health prob-
lem when compared with no use (Vanasse et al., 2016; Tiihonen 
et al., 2017). However, there is still a debate about what is the 
optimal long-term treatment for patients with an FEP. Although 
second-generation antipsychotics (SGAs) seem to be the main-
stay of treatment to improve the long-term prognosis of people 
with an FEP, there is scarce information about their differen-
tial effectiveness in the long term (Crespo-Facorro et al., 2012). 
These differences among SGAs in terms of effectiveness might 
be a key point to optimize the selection of the most appropriate 
antipsychotic in FEP patients (Shrivastava et al., 2010; San et al., 
2012). Nonetheless, direct comparisons between the different 
SGAs are limited in real world clinical practice (Crespo-Facorro 
et  al., 2014). All-cause time to treatment discontinuation has 
been accepted as a proxy measure of effectiveness, incorporat-
ing a measure of tolerability (absence of significant side effects) 
of the medication and clinical efficacy (Lieberman et al., 2005; 
Kahn et  al., 2008). A  recent systematic review and pairwise 
meta-analysis suggested that there is little evidence on which 
to base drug choice in terms of efficacy in patients presenting 
with first-episode schizophrenia, so that treatment decisions 
in this population should be guided by side-effect profiles (Zhu 
et al., 2017). Previous studies investigating the effectiveness of 
different SGAs in the short (Crespo-Facorro et al., 2013; Robinson 
et al., 2015) and mid-term have revealed significant differences 
in terms of risk of treatment discontinuation SGAs (Lieberman 
et al., 2005; Robinson et al., 2005; Ciudad et al., 2008; Kahn et al., 
2008; Johnsen et al., 2010; Crespo-Facorro et al., 2012; San et al., 
2012; Noguera et al., 2013; Zhu et al., 2017). Specific short-mid- 
and long-term distinctions in clinical efficacy and safety profiles 
of individual antipsychotics may determine changes in SGAs 
effectiveness across time. Our study provides a large follow-up 
period of 3 years, which is an important variable when compar-
ing antipsychotic retention rates (as discontinuation rates gen-
erally increase with time) and a sample almost fully integrated 
by antipsychotic-naïve FEP patients.
Our hypothesis was that the use of aripiprazole, ziprasi-
done, or quetiapine to treat individuals with an FEP in our study 
would result in different effectiveness in the long term (3 years). 
Second, we hypothesized that disparity in efficacy, adherence, 
and side-effect occurrence may mediate these differences in 
terms of effectiveness. The aim of this study was to compare dir-
ectly 3 widely used SGAs and identify differences among them 
regarding the risks and benefits of each one to guide decisions 
about prescribing treatment of individuals presenting with FEP.
Experimental procedures
Study Setting
Data for the present investigation were obtained from an 
ongoing epidemiological and 3-year longitudinal intervention 
program of first-episode psychosis called Programa de Atención 
a Fases Iniciales de Psicosis (PAFIP) conducted at the outpatient 
clinic and inpatient unit of the University Hospital Marqués 
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de Valdecilla, Spain (Pelayo-Terán et  al., 2008). Conforming 
to international standards for research ethics, this program 
was approved by the local institutional review board. Patients 
meeting inclusion criteria and their families provided written 
informed consent prior to their inclusion in the program.
Subjects
From October 2005 to January 2011, all referrals to PAFIP were 
screened for patients who met the following criteria: (1) 15 to 
60 years; (2) living in the catchment area; (3) experiencing their 
FEP; (4) no prior treatment with antipsychotic medication or, if 
previously treated, a total lifetime of adequate antipsychotic 
treatment of <6 weeks; and (5) DSM-IV criteria for brief psych-
otic disorder, schizophreniform disorder, schizophrenia, or 
schizoaffective disorder. Patients were excluded for any of the 
following reasons: (1) meeting DSM-IV criteria for drug depend-
ence, (2) meeting DSM-IV criteria for mental retardation, or (3) 
having a history of neurological disease or head injury. The diag-
noses were confirmed using the Structured Clinical Interview 
for DSM-IV (First et  al., 2002) carried out by an experienced 
psychiatrist 6 months after the baseline visit. Our operational 
definition for an FEP included individuals with a nonaffective 
psychosis (meeting the inclusion criteria defined above) who 
had not received previous antipsychotic treatment regardless of 
the duration of psychosis.
Study Design
This was a prospective, randomized, flexible dose, open-label 
study. We used a simple randomization procedure. An auto-
mated randomization list was drawn up. At study intake, all 
patients but 8 were antipsychotic naïve. Before starting on the 
assigned drug, these subjects underwent a 2- to 4-day washout 
period. Mean antipsychotic doses expressed as chlorpromaz-
ine equivalents (mg/d) (Woods, 2003) were as follow: quetiapine 
100 to 600 mg/d (133.33–800 mg/d of chlorpromazine), ziprasi-
done 40 to 160  mg/d (66.67–266.67  mg/d of chlorpromazine), 
and aripiprazole 5 to 30 mg/d (66.67–400 mg/d of chlorpromaz-
ine). A rapid titration schedule (5 days), until optimal dose was 
reached, was used as a rule unless severe side effects occurred. 
At the treating psychiatrist’s discretion, the dose and type of 
antipsychotic medication could be changed based on clinical 
efficacy and the profile of side effects during the follow-up 
period. Anticholinergic medications, lormetazepam and clon-
azepam, were permitted for clinical reasons. No anticholinergic 
agents were administered prophylactically. Antidepressants and 
mood stabilizers were permitted if clinically needed. The sever-
ity scale of the Clinical Global Impression (CGI) scale (Guy, 1976), 
the Brief Psychiatric Rating Scale (BPRS) (expanded version of 24 
items) (Overall and Gorham, 1962), the Scale for the Assessment 
of Positive symptoms (SAPS) (Andreasen, 1984), the Scale for 
the Assessment of Negative symptoms (SANS) (Andreasen, 
1989), the Calgary Depression Scale for Schizophrenia (CDSS) 
(Addington et  al., 1993), and the Young Mania Rating Scale 
(YMRS) (Young et al., 1978) were used to evaluate clinical symp-
tomatology. The scale of the Udvalg for Kliniske Undersogelser 
(Committee of Clinical Trials) (Lingjærde et  al., 1987), the 
Simpson-Angus Rating Scale (SARS) (Simpson and Angus, 1970) 
and the Barnes Akathisia Scale (BAS) (Barnes, 1989) were used 
to assess side effects. Clinical assessments and measurements 
were completed at baseline, at 3 weeks, at 6 weeks, 3 months, 
6 months, 12 months, 18 months, 24 months, 30 months, and 
36 months. All patients included in the analysis had at least the 
baseline and 3-year assessments and were considered for drop-
out in those cases in which they did not attend 2 consecutive 
check-point assessments. The same trained psychiatrist (B.C.-F.) 
completed all clinical assessments.
Outcome Measures
Primary Outcome Measures: Effectiveness
The main outcome of effectiveness was the treatment dis-
continuation rate, which is the percentage of all-cause dis-
continuation of the initially assigned treatment (patients who 
completed the 3-year follow-up assessment and changed their 
initial antipsychotic) and the mean time to all-cause medication 
discontinuation (two accepted indexes of medication effective-
ness). Four reasons for the discontinuation were recorded: (1) 
nonefficacy or insufficient efficacy, (2) significant side effects, (3) 
nonadherence, and (4) other causes.
Insufficient efficacy was established at the treating phy-
sician’s judgment only after at least 3 weeks of treatment. 
Adherence to antipsychotic drugs was assessed by information 
obtained from patients, close relatives, and the staff (nurses, 
social workers, and psychiatrists) involved in the follow-up. For 
the present investigation, patients were consensually dichoto-
mized into having a good (defined as patients regularly taking 
at least 90% of prescribed medication) and a poor adherence 
(medium or poor compliance). If more than one reason for dis-
continuation was present, the most important reason according 
to the above ranking was selected.
Secondary Outcome Measures: Efficacy and Safety
The efficacy outcomes were the mean change from baseline 
to 3 years in BPRS, SAPS, and SANS total scores. Additional 
analyses included changes from baseline to 3 years in CGI, 
YMRS, and CDSS total scores. Patients were defined as 
responders to the optimum dose of antipsychotic if they 
had a ≥50% reduction of BPRS total score and a CGI severity 
score ≤4 after 6 months since the beginning of the treatment. 
Side effects were evaluated using the Udvalg for Kliniske 
Undersogelser side effect rating scale. Those treatment-
emergent side effects that occurred at a rate of at least 5% 
in either treatment group at any time during the follow-up 
period were considered. Only those side effects rated as 
moderate or severe and with a possible causal relationship 
to medication were recorded. Treatment-emergent akathisia 
and extrapyramidal symptoms were assessed using BAS 
and SARS scales, respectively. Treatment-emergent parkin-
sonism was defined as a total score >3 on the SARS at any 
of the check-point assessments, given a total score of ≤3 at 
baseline.
Statistical Analyses
All data were tested for normality (Kolmogorov-Smirnov test) 
and equality of variances (Levene test). To ensure group compar-
ability, baseline sociodemographic and clinical characteristics 
were tested by 1-way ANOVA or Kruskal-Wallis test for continu-
ous variables as necessary or by chi-squared test for qualitative 
variables.
Kaplan-Meier survival curves and a log-rank test were 
used to assess time to all-cause medication discontinuation. 
Concerning these 2 analyses, patients were followed-up from the 
inclusion in the study until discontinuation of the initial treat-
ment or censoring. Survival time could be censored by the end 
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of the observation period or by loss to follow-up (patients who 
dropped out before discontinuation of the initial treatment).
For efficacy and safety measures related to side effects, this 
research adopted an intention-to-treat analysis paradigm, and 
patients were followed-up for at least 3 years after their inclu-
sion regardless of whether they had switched their randomly 
assigned treatment, with the exception of those patients who 
dropped out of the study and were thus unable to complete the 
follow-up. In addition, per protocol analyses were performed 
and are available upon request.
Differences between groups in the degree of change in clin-
ical scores from baseline were evaluated with ANCOVA after 
baseline scores were controlled. Finally, comparisons of the dis-
continuation rates and the prevalence of side effects as well as 
the use of concomitant treatment between the 3 antipsychotics 
were carried out, performing chi-square tests with Bonferroni 
correction for multiple comparisons when necessary.
STATA 15.0 was used for statistical analysis. Statistical tests 
were 2-tailed with a 95% CI.
Results
Of 224 individuals initially randomized to treatments, 22 were 
finally removed from the dataset because it was verified they 
did not fully meet inclusion criteria or removed proper written 
consent during the first week. Thus, the final sample consisted 
of 202 subjects: 78 patients were randomly assigned to the 
aripiprazole group, and 62 patients were randomly assigned to 
both the quetiapine and ziprasidone groups (Figure 1). At base-
line, only 8 (4.0%) patients reported some prior antipsychotic 
treatment. The mean self-reported duration of prior treatment 
was 1.5 weeka (SD = 1.3; range, 0.4–4.0). The overall dropout rate 
at 3 years was small (n = 39; 19.3%: 12 aripiprazole, 10 ziprasi-
done, and 17 quetiapine). A total 22 patients dropped out of the 
follow-up prior to treatment discontinuation and were censored 
for the survival analysis (9 aripiprazole, 8 quetiapine, and 5 
ziprasidone). Four patients committed suicide during the 3-year 
follow-up (1 aripiprazole, 1 ziprasidone, and 2 quetiapine) and 
there was one sudden death (aripiprazole; heart attack). All but 
10 individuals were white Caucasian. Demographic and clinical 
characteristics of patients are shown in Table 1.
Primary Outcome Measures
Treatment Discontinuation Rate and Time to Discontinuation
The all-cause treatment discontinuation rate differed signifi-
cantly between treatment groups (χ2 = 11.680; P = .001) (Table 2). 
Patients on quetiapine showed a higher (95.16 %) treatment 
discontinuation rate than patients taking aripiprazole (73.08 
%) or ziprasidone (79.03 %). The time (days) until approxi-
mately 50% of the patients left their initial treatment due to 
any cause was 452 days for aripiprazole, 251 days for ziprasi-
done, and 60 days for quetiapine. There was a significant dif-
ference between groups in median time to discontinuation 
Figure 1. Consort flow diagram of subject through the phases of the randomized trial.
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(log rank = 32.260; P = .001) (Figure  2). Log-rank pairwise 
comparisons between treatment groups showed the follow-
ing results: aripiprazole vs quetiapine (χ2 = 28.95; P = .000), 
ziprasidone vs quetiapine (χ2 = 14.29; P = .000), and aripipra-
zole vs ziprasidone (χ2 = 2.02; P = .156). Consequently, we 
found statistically significant differences between aripipra-
zole and quetiapine and between ziprasidone and quetiapine 
but not between aripiprazole and ziprasidone, where we only 
found a trend towards nondiscontinuation favoring aripipra-
zole. Nonefficacy or insufficient efficacy in the quetiapine 
group was the main reason for discontinuation rate differ-
ences (χ2 = 22.694; P = .000). Patients under quetiapine treat-
ment were significantly more likely to discontinue due to 
nonefficacy or insufficient efficacy compared with aripipra-
zole (χ2 = 19.450; P = .000) or ziprasidone patients (χ2 = 11.414; 
P = .000). No significant differences were found between 
the aripiprazole and ziprasidone groups in terms of nonef-
ficacy or insufficient efficacy (χ2 = 0.734; P = 1.0). Mean (SD) 
doses prior to discontinuation due to nonefficacy or insuf-
ficient efficacy were: aripiprazole, 15.7 mg (8.6); ziprasidone, 
Table 1. Demographic and Clinical Characteristics of 202 Drug-Naïve Patients with a First Episode of Psychosis Randomly Assigned to Treatment 









Characteristics Mean SD Mean SD Mean SD Mean SD  Statistics  P
Age at admission (years) 32.0 10.3 31.0 9.2 32.1 10.5 32.6 11.1 F = 0.419 .658
Age at psychosis onset 
(years)
30.8 9.9 30.3 9.2 31.1 10.6 30.9 9.9 F = 0.127 .888
Duration of illnessa 
(months)
23.8 45.5 22.1 42.8 16.4 29.4 31.1 56.4 z = 0.658 .720
Duration of psychosis 
(months)
2.81 19.0 3.0 11.0 2.25 9.0 2.25 17.1 z = 0.226 .893
N % N % N % N %  χ2  P
Schizophrenia diagnosis 113 55.9 38 61.3 36 58.6 39 50.0 1.931 .372
Sex (male) 108 53.5 41 66.1 29 46.8 38 48.7 5.819 .055
Race (white) 192 95.0 58 93.5 94 93.5 76 97.4 1.538 .464
Education level 
(elementary)
95 47.3 38 61.3 27 43.5 30 39.0 7.367 .025
Socioeconomic status 
of parents (not/less 
qualified)
92 45.8 30 48.4 28 45.2 34 44.2 0.261 .878
Urban area (yes) 150 74.6 48 77.4 46 74.2 56 72.7 0.408 .815
Living with parents (yes) 93 46.3 33 53.2 29 46.8 31 40.3 2.332 .312
Student (yes) 39 19.4 8 12.9 15 24.2 16 20.8 2.678 .262
Single (yes) 135 67.2 41 66.1 44 71.0 50 64.9 0.610 .737
Unemployed (yes) 90 44.8 32 51.6 23 37.1 35 45.5 2.665 .264
Occupational status (yes) 94 46.8 25 40.3 33 53.2 36 46.8 2.073 .355
Family psychiatric history 
(yes)
48 23.8 14 22.6 17 27.4 17 21.8 0.672 .715
Hospital status inpatient 
(yes)
134 66.3 41 66.1 41 66.1 52 66.7 0.006 .997
Tobacco use (yes) 119 58.9 39 62.9 33 53.2 47 60.3 1.294 .524
Cannabis use (yes) 79 39.1 29 46.8 20 32.3 30 38.5 2.765 .251
Alcohol use (yes) 108 53.5 39 62.9 29 46.8 40 51.3 3.485 .175
Other drugs (yes) 39 19.4 18 29.0 6 9.7 15 19.5 7.426 .024
aDuration of illness was available on aripiprazole = 76, ziprasidone = 61, and quetiapine = 59.
Table 2. Any-Cause Discontinuation Rate and Discontinuation Rates by Allocated Causes
Total Aripiprazole Quetiapine Ziprasidone
(n = 202) (n = 78) (n = 62) (n = 62)
N % N % N % N % χ2 P
Any-cause 
discontinuation
165 81.68 57 73.08 59 95.16 49 79.03 11.680 .000
No efficacy 56 27.72 12 15.38 31 50.00 13 20.97 22.694 .000
No adherence 46 22.77 26 33.33 12 19.35 8  12.90 8.792 .012
Secondary effects 41 20.29 10 12.82 8 12.90 23  37.10 15.607 .000
Dropout 22 10.89 9 11.53 8 12.90 5  8.06 0.803 .699
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80.4  mg (40.3); and quetiapine, 490  mg (251.1). Analysis of 
treatment discontinuation because of side effects showed 
significant differences between treatment groups (que-
tiapine 12.9%, ziprasidone 37.1%, and aripiprazole 12.82%; 
χ2 = 15.607; P = .000). Patients initially treated with ziprasi-
done discontinued treatment significantly more frequently 
than those on aripiprazole (χ2 = 11.300; P = .002) or quetiapine 
(χ2 = 9.677; P = .006) due to side effects. Regarding the direct 
comparison between quetiapine and aripiprazole, no signifi-
cant differences were found (χ2 = 0.000; P = 1.0). Finally, there 
is a remarkable difference in terms of treatment adherence. 
After intention-to treat analysis, individuals in the aripipra-
zole group showed worse compliance than those individu-
als in the ziprasidone group (χ2 = 8.792; P = .012); however, no 
differences were found between the aripiprazole and quetia-
pine groups (χ2 = 3.413; P = .194) or between the ziprasidone 
and quetiapine groups (χ2 = 0.954; P = .986). In those patients 
who continued taking the initial prescribed drug, mean 
antipsychotic doses at 3  years, adjusted in chlorpromaz-
ine equivalents, were aripiprazole, 216.8 (SD = 164.1) mg/d; 
ziprasidone, 202.2 (SD = 136.5) mg/d; and quetiapine, 261.1 
(SD = 136.5) mg/d, with no significant differences observed 
(P = .279) between treatment groups.
Secondary Outcome Measures
Clinical Efficacy
Intention-to-treat analyses showed that there were no stat-
istically significant differences between treatment groups in 
the severity of symptoms at baseline and at 3 years except for 
BPRS (P = .043) and CGI (P = .040) at baseline (Table 3). Posthoc 
analyses with Bonferroni correction found statistically sig-
nificant differences between aripiprazole and ziprasidone 
in the BPRS (P = .030) and CGI scales (P = .035) at baseline. 
ANCOVA analyses showed no differences in the changes of 
the total scores of the clinical scales between treatments (all 
P > .1) after controlling by baseline measurements except for 
the CDSS (P = .026); Bonferroni correction was significant for 
the comparison between aripiprazole and quetiapine for the 
CDSS (P = .030).
The rate of responders was also similar between aripiprazole, 
ziprasidone, and quetiapine (56.28%, 52.84%, 52.11%, respect-
ively; F = 1.25, P = .293). All treatments decreased at least 4 points 
on the CGI scale from baseline to 3 years (Table 3). Statistically 
significant differences between treatments were not found 
(F = 0.41; P = .664).
Safety
Adverse Events
Intention-to-treat analyses of moderate and severe side effects 
that were frequent (in at least 5% of patients in any of the treat-
ment groups) are displayed in Table  4. Significant differences 
between treatments were found in the categories of sleepi-
ness/sedation (χ2 = 9.617; P = .008) and increased sleep duration 
(χ2 = 6.192; P = .004). After adjustment by Bonferroni correction, 
statistically significant differences were only found when com-
paring aripiprazole and quetiapine for sleepiness/sedation 
(P = .007) and increased sleep duration (P = .05). No significant dif-
ferences between treatments were found after performing per-
protocol analysis (data available upon request).
Extrapyramidal Symptoms
Intention-to-treat analyses have shown no significant differ-
ences in the increment of extrapyramidal signs at 3 years (SARS 
total score) between treatments (F = 0.132; P = .936). The per-
centage of patients with treatment-emergent extrapyramidal 
symptoms  (EPS) was not statistically different between treat-
ment arms (aripiprazole = 17.8%; ziprasidone = 17.3%, and que-
tiapine 15.4%; χ2 = 0.461; P = .794). Per-protocol analysis showed 
rather similar results (data available upon request). There was 
no significant difference between treatments in the severity 
of akathisia (BAS total score) (F = 0.532; P = .588). Although the 
difference did not reach a significant level, a higher number of 
individuals in the aripiprazole (22.6%) and ziprasidone groups 
(32.7%) experienced treatment-emergent akathisia (BAS global 
score of 2 or more at check-point evaluations, given a global 
score of <2 at baseline visit) compared with quetiapine-treated 
subjects (17.8%) (χ2 = 3.910; P = .142).
Concomitant Medication Use
Intention-to-treat analyses showed no significant differ-
ences between antipsychotic treatment groups regarding the 
use of concomitant medication, except for benzodiazepines 
(χ2 = 10.76, P = .005). After adjustment by Bonferroni correction, 
chi-square tests revealed that benzodiazepine use in the ari-
piprazole group was significantly higher than in the quetiapine 
group (92.3% vs 72.6%; χ2 = 9.791, P = .005). However, there were 
no statistically significant differences in the use of benzodi-
azepines between the aripiprazole group and the ziprasidone 
group (92.3% vs 87.1%; χ2 = 1.042, P = .921) or between the quetia-
pine group and the ziprasidone group (72.6% vs 87.1%; χ2 = 4.06, 
P = .132).
Figure 2. Kaplan-Meyer survival graph: All-cause discontinuation.
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Discussion
In previous studies, aripiprazole and ziprasidone demonstrated 
significantly higher effectiveness (lower all-cause treatment dis-
continuation rates and mean time to discontinuation) than quetia-
pine in the acute treatment of an FEP. This trend was confirmed 
after a 3-year follow-up. Nonefficacy or insufficient efficacy in the 
quetiapine group was the main reason for discontinuation rate dif-
ferences between antipsychotics. The profile of motor side effects 
varied between treatments, as did the ability of each group to 
adhere to treatment. These factors may contribute to additional dif-
ferences in terms of effectiveness. Instead, intention-to-treat ana-
lysis revealed no treatment advantages in reducing the severity of 
symptomatology (efficacy) between the 3 SGAs.
Table 3. Intention-to-Treat Sample: Psychopathological Characteristics at Baseline and 3 Years and Clinical Changes during the Follow-Up 
Period 
Total sample Aripiprazole Quetiapine Ziprasidone
n = 163 n = 66 n = 45 n = 52
Mean SD Mean SD Mean SD Mean SD F P
SAPS
Baseline 14.2 4.3 14.6 4.4 13.9 4.1 13.9 4.3 0.526 .592
3 Years 1.1 2.8 1.0 2.8 1.4 3.0 1.1 2.7 0.314 .731
Changea -13.0 4.8 -13.6 4.7 -12.5 5.3 -12.8 4.6 0.786 .458
Changeb -13.2 0.3 -12.7 0.4 -13.1 0.4 0.384 .681
SANS
Baseline 6.7 6.1 7.5 6.8 6.3 6.0 6.1 5.4 0.906 .406
3 Years 3.6 5.4 3.9 5.7 3.8 5.8 3.1 4.8 0.384 .682
Changea -3.1 7.3 -3.6 8.3 -2.5 5.7 -3.0 7.5 0.287 .751
Changeb -2.9 0.7 -2.8 0.8 -3.5 0.7 0.252 .778
BPRS
Baseline 64.7 12.6 67.7 12.6 63.9 12.0 61.7 12.6 3.524 .032
3 Years 29.9 8.8 29.6 10.0 30.6 9.8 29.1 7.3 0.340 .714
Changea -34.9 13.8 -38.0 15.0 -33.3 13.7 -32.6 12.0 2.712 .069
Changeb -35.5 1.1 -34.0 1.3 -35.2 1.3 0.403 .670
CGI
Baseline 6.5 0.6 6.6 0.6 6.5 0.6 6.3 0.6 3.280 .040
3 Years 2.4 1.6 2.5 1.7 2.5 1.8 2.1 1.4 0.725 .486
Changea -4.2 1.7 -4.2 1.7 -4.1 1.9 -4.2 1.5 0.092 .912
Changeb -4.1 0.2 -4.1 0.2 -4.3 0.2 0.410 .664
Positive dimension
Baseline 7.5 2.4 7.6 2.6 7.6 2.4 7.3 2.3 1.471 .233
3 Years 0.7 1.7 0.5 1.8 1.0 1.9 0.5 1.3 0.424 .655
Changea -6.8 2.8 -7.0 2.8 -6.6 3.0 -6.8 2.6 0.229 .795
Changeb -7.0 0.2 -6.5 0.2 -6.9 0.2 1.420 .245
Disorganized dimension
Baseline 6.7 3.3 7.0 3.2 6.3 3.2 6.6 3.5 0.631 .534
3 Years 0.5 1.6 0.5 1.5 0.4 1.4 0.6 1.8 0.122 .885
Changea -6.2 3.6 -6.5 3.6 -5.9 3.6 -6.0 3.6 0.488 .615
Changeb -6.2 0.2 -6.3 0.2 -6.1 0.2 0.112 .894
Negative dimension
Baseline 4.5 5.4 5.0 6.0 4.3 5.4 3.9 4.7 0.628 .535
3 Years 3.2 4.9 3.5 5.1 3.3 5.1 2.8 4.4 0.326 .722
Changea -1.3 6.4 -1.6 7.2 -1.0 5.0 -1.2 6.5 0.115 .891
Changeb -1.1 0.6 -1.1 0.7 -1.6 0.7 0.182 .834
YMRS
Baseline 11.9 5.0 11.8 5.0 12.3 5.5 11.7 4.6 0.252 .777
3 Years 1.4 3.3 1.0 2.2 1.9 3.6 1.5 4.1 1.073 .345
Changea -10.5 5.4 -10.8 5.0 -10.4 6.8 -10.1 4.7 0.204 .816
Changeb -10.9 0.4 -10.0 0.5 -10.3 0.5 0.974 .380
CDSS
Baseline 2.5 3.5 2.8 3.6 2.7 3.3 2.0 3.5 0.852 .428
3 Years 0.4 1.3 0.7 1.8 0.1 0.3 0.3 0.9 3.753 .026
Changea -2.1 3.7 -2.1 4.1 -2.6 3.3 -1.8 3.5 0.669 .514
Changeb -1.8 0.2 -2.5 0.2 -2.3 0.2 3.719 .026
Abbreviations: BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Rating Scale for Schizophrenia; CGI, Clinical Global Impression; 
SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; YMRS, Young Mania Rating Scale. 
a3-Year change from baseline.
b3-Year change from baseline after controlling for baseline.
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Effectiveness
An impressive 80.69 % of the initial sample completed follow-
up. The overall treatment discontinuation rate (the cumula-
tive percentage of discontinuation considering the 3 arms of 
the study) reached 81.7% by 3 years, which is in line with other 
medium and long-term (52 weeks or more) follow-up studies 
(Lieberman et al., 2005; McEvoy et al., 2007; Kahn et al., 2008; 
Mullins et al., 2008; Johnsen et al., 2010; Crespo-Facorro et al., 
2012, 2014; San et al., 2012; Noguera et al., 2013). Interestingly, 
more than three-quarters of the patients who discontinued 
treatment did so during the first year of follow-up (76.4% by the 
end of year 1), in agreement with the studies mentioned previ-
ously. Such a high all-cause discontinuation rate represents a 
major issue, considering that adherence to maintenance treat-
ment is the primary aim in FEP patients (San et al., 2012) after 
remission in order to prevent relapse. The all-cause treatment 
discontinuation rate in our sample was significantly greater in 
the quetiapine group, mainly due to nonefficacy or insufficient 
efficacy. Higher risk of all-cause treatment discontinuation in 
quetiapine patients had already been described during early 
phases of treatment (Ciudad et al., 2008; Crespo-Facorro et al., 
2014). The median time to all-cause discontinuation in the que-
tiapine group was significantly shorter (60  days) than in the 
other 2 treatment groups: 452 days in the aripiprazole group and 
251  days in the ziprasidone group. Despite no significant dif-
ferences between aripiprazole and ziprasidone, there is a clear 
trend favoring aripiprazole, as can be observed on the K-M sur-
vival graph. Both aripiprazole and ziprasidone showed statis-
tically significant superiority over quetiapine regarding median 
time to all-cause treatment discontinuation. We found that 
discontinuation because of nonefficacy or insufficient efficacy 
was higher in quetiapine (50.0%) compared with aripiprazole 
(15.38%) and ziprasidone (20.97%). Effectiveness studies using 
standard dosage ranges pointed out that quetiapine may be less 
effective than some other widely used SGAs (Ciudad et al., 2008; 
Asmal et al., 2013; Leucht et al., 2013; Tiihonen, 2016) and FGAs 
(Vanasse et  al., 2016). Regarding the latter study, the authors 
also warned about a higher risk for health events related to 
quetiapine. Our results are consistent with the notion that 
most of the patients who start quetiapine stop taking it within 
a few weeks (Asmal et  al., 2013). Inadequate and transient 
dopamine−2 receptor occupancy has been proposed as a pos-
sible mechanism underlying quetiapine lack of efficacy. On the 
other hand, its weak dopamine antagonism allows low max-
imal occupancy values and relatively little variability in occu-
pancy values, suggesting that high doses of this antipsychotic 
are not likely to exceed thresholds of more than 80% occupancy, 
indicative for D2-receptor-mediated side effects (Lako et  al., 
2013). This supports the idea that higher doses may be tolerable 
and more efficient (McEvoy et al., 2007). We did not find signifi-
cant differences between groups concerning treatment dosage 
adjusted by chlorpromazine equivalents prior to discontinu-
ation due to nonefficacy or insufficient efficacy. The quetiapine 
group presented with a higher relative dosage compared with 
the other groups. According to other reports (Tiihonen et  al., 
2017), it is difficult to discern whether the poorer performance 
of quetiapine is due to the product itself or to nonoptimal dos-
age. It is of note that ziprasidone and aripiprazole all-cause dis-
continuations seem to occur later during treatment, likely due 
to the emergence of side effects (37.1% in ziprasidone group) 
and nonadherence (33.3% in aripiprazole group), respectively. 
Actually, most all-cuase discontinuations in the ziprasidone 
sample due to secondary effects (65.2%) took place between 6 
and 18 months of follow-up. Finally, most aripiprazole discon-
tinuations were due to nonadherence (53.8%) and accumulated 
Table 4. Intention-to-Treat Sample: Moderate or Severe Treatment-Emergent Adverse Effects That Occurred at a Rate of at Least 5% in Either 
Treatment Group
Total Aripiprazole Quetiapine Ziprasidone
6-weeks to 3 years (n = 163) % (n = 66) % (n = 45) % (n = 52) % χ2 P
Concentration difficulties 29 17.8 13 19.7 6 13.3 10 19.2 0.849 .654
Asthenia/increased 
fatigability
74 45.4 26 39.4 24 53.3 24 46.2 2.115 .347
Sleepiness/sedation 86 52.8 26 39.4 31 68.9 29 55.8 9.617 .008
Memory impairmment 7 4.3 3 4.5 1 2.2 3 5.8 0.755 .685
Depression 7 4.3 3 4.5 1 2.2 3 5.8 0.755 .685
Restlessness 7 4.3 3 4.5 1 2.2 3 5.8 0.755 .685
Increased sleep duration 52 31.9 14 21.2 19 42.2 19 36.5 6.192 .045
Rigidity 9 5.5 2 3.0 1 2.2 6 11.5 5.333 .069
Akinesia 46 28.2 23 34.8 8 17.8 15 28.8 3.864 .145
Tremor 14 8.6 9 13.6 2 4.4 3 5.8 3.653 .161
Akathisia 39 23.9 15 22.7 8 17.8 16 30.8 2.325 .313
Increased salivation 29 17.8 11 16.7 9 20.0 9 17.3 0.215 .898
No salivation 22 13.5 5 7.6 8 17.8 9 17.3 3.335 .189
Constipation 19 11.7 7 10.6 7 15.6 5 9.6 0.945 .623
Miction impairment 6 3.7 4 6.1 1 2.2 1 1.9 1.777 .411
Vertigo 7 4.3 3 4.5 0 0.0 4 7.7 3.490 .175
Weight gain 68 41.7 32 48.5 20 44.4 16 30.8 3.944 .139
Diminished sexual desire 16 9.8 6 9.1 6 13.3 4 7.7 0.933 .627
Orgasmic dysfunction 6 3.7 1 1.5 2 4.4 3 5.8 1.587 .452
Amenorrhea 12 14.8 5 14.3 0 0.0 7 23.3 4.515 .105
Galactorrhea 2 2.5 0 0.0 0 0.0 2 6.7 3.486 .175
Erectile dysfunction 14 17.1 2 6.5 7 24.1 5 22.7 3.989 .136
Ejaculatory dysfunction 13 15.9 2 6.5 6 20.7 5 22.7 3.342 .188
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between the second and third years of follow-up. In this sense, 
aripiprazole seems to be the most effective and tolerable of the 
trio. The increase in discontinuations due to nonadherence 
observed during the last year of follow-up in this group might 
be explained by a natural decrease in the acceptability of treat-
ment mediated by long-term exposure to treatment (Lieberman 
et al., 2005). Improvements in educational and other prophylac-
tical measures like the use of long-acting injectable formula-
tions (Jann and Penzak, 2018) may be of interest to deal with 
this preventable issue.
Efficacy
Our first-episode patients showed a decrease in total BPRS, 
SAPS, SANS, and CGI scores during the 3-year follow-up. 
The finding of no significant differences between treatment 
groups regarding the decrease in these clinical efficacy 
scales and responder rates agrees with previous reports 
(McEvoy et al., 2007; San et al., 2012). Remarkably, one-half 
of quetiapine discontinuations were due to nonefficacy or 
insufficient efficacy. The absence of differences observed 
in efficacy measures at 3 years may be attributable to the 
efficacy of the subsequent antipsychotic employed after 
initial treatment discontinuation. Differences in depres-
sive symptom improvement between quetiapine and ari-
piprazole were observed, favoring the quetiapine group. 
Open-label trials had pointed out that quetiapine may be a 
useful agent in the management of depressive symptoms in 
individuals with psychosis (Samara et al., 2015). Quetiapine 
is acknowledged as a first-line treatment even in mono-
therapy in affective-psychoses (Lindström et al., 2017), but 
in several previous first-episode nonaffective psychoses 
studies, no significant differences between SGAs (includ-
ing quetiapine) had been found in reducing depressive 
symptoms after mid-term follow-up (McEvoy et  al., 2007; 
Kahn et  al., 2008; Crespo-Facorro et  al., 2014). No notable 
changes on negative symptoms were found with any of the 
3 antipsychotics.
Side Effects and Concomitant Medications
The differences in the percentage of patients with treatment-
emergent parkinsonism though, nonstatistically significant, 
may be of clinical interest. A  higher percentage of extrapy-
ramidal side effects and akathisia (Juncal-Ruiz et  al., 2017) in 
aripiprazole and ziprasidone-treated individuals during the 
acute treatment of a first episode has been described. A higher 
incidence of akathisia early after aripiprazole and ziprasidone 
treatment was initiated has also been previously reported 
(Kerwin et  al., 2007). This circumstance may partially explain 
that significantly more patients on aripiprazole needed ben-
zodiazepines to relieve akathisia in our sample. In agreement 
with previous reports (Lee et al., 2011; Vázquez-Bourgon et al., 
2018), no significant differences were found in the frequency of 
body weight increase between treatments, but a uniform trend 
to weight increase was appreciated with all of them. Intention-
to-treat analysis revealed that 44.4% of the individuals on que-
tiapine, 48.5% on aripiprazole, and 30.8% on ziprasidone showed 
a rapid body weight gain (Table 4). Interestingly, the percentage 
of discontinuation due to severe or intolerable side effects in our 
study was relatively low (20.9 %) but significant in the case of 
ziprasidone, because it was its main cause of discontinuation 
(37.1%). Sleepiness/sedation was the most prevalent reported 
secondary effect for discontinuation in the case of ziprasidone 
(n = 8; 34.7%) despite low doses prior to discontinuation due to 
secondary effects (58.5 mg [SD = 34.3]).
Limitations and Strengths
Several limitations should be considered when interpreting our 
results. First, as a practical clinical trial, patients and observers 
(B.C.-F.) were not blinded to treatments in our study. The fact 
that the observers knew the medications prescribed may have 
involuntarily biased the outcomes. As a non-industry-funded 
study, the risk for systematic biased measuring study outcomes 
favoring any of the 3 SGAs is limited. Second, the mean doses of 
quetiapine used could be understood as somewhat low to treat 
first-episode individuals. However, controlled investigations 
have clearly confirmed that standard dosage range should be 
appropriate in everyday clinical practice (Johnsen and Jörgensen, 
2008). Optimal doses of antipsychotics within the licensed range 
were chosen based on clinical efficacy and the presence of side 
effects and were adjusted according to the clinical situation of 
each patient. Treatment compliance measures were collected 
from self-report and close observers (family members and social 
assistants) but not from antipsychotic blood levels. This could 
have an impact in the accuracy of discontinuation measures 
due to noncompliance. On the other hand, this is one of the 
longest effectiveness studies regarding to follow-up (3 years). It 
was performed on a well-characterized and homogeneous sam-
ple, because most of patients (96%) were antipsychotic naïve 
prior to their inclusion.
Conclusions
Patients on quetiapine were more likely to discontinue treatment 
after an FEP globally and specifically at short and medium term due 
to nonefficacy or insufficient efficacy compared with aripiprazole 
and ziprasidone patients. Ziprasidone patients showed a greater ten-
dency to discontinuation subordinated to persistent side effects in 
the mid-term. Finally, the majority of aripiprazole patients (the group 
with the longer time prior to discontinuation) who quit treatment 
did so in the last phase of follow-up (most of them reporting non-
adherence). In summary, guaranteeing good adherence to effective 
antipsychotic treatment is one of the main challenges in the treat-
ment of FEP individuals to prevent a malignant course of the disease. 
Establishing differences between SGAs regarding to risks and ben-
efits of treatments and identifying different discontinuation patterns 
may contribute to optimize treatment selection after an FEP.
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